Diastolic hypotension in pediatric patients with asthma receiving continuous albuterol.
OBJECTIVE
Concerns have been raised regarding cardiac side effects of continuous high-dose albuterol nebulization in status asthmaticus management. Our study goal was to determine prevalence and potential risk factors for hypotension development during continuous albuterol administration in pediatric patients.


METHODS
A retrospective cohort study was conducted at Children's Memorial Hermann Hospital from 1 January 2011 to 31 August 2012. A total of 152 patients admitted to pediatric intensive or intermediate care units who received continuous albuterol nebulization for management of status asthmaticus were analyzed.


RESULTS
Diastolic hypotension, defined as a value < 50 mmHg or <5th percentile of normal for age, developed in 90% of patients and a positive correlation with increasing doses of albuterol was demonstrated. The overall median time to onset of hypotension was 4 h (interquartile range (IQR): 2-6.5) and was significantly lower among patients admitted to the intensive care unit rather than intermediate care (p = 0.005). The odds of hypotension were 82% lower among patients who received fluid boluses prior to continuous albuterol nebulization. None of the potential risk factors demonstrated statistical significance.


CONCLUSIONS
Diastolic hypotension is a common occurrence among patients who receive continuous albuterol nebulization for status asthmaticus. Total albuterol dose appeared to be directly related to risk of developing diastolic hypotension. Administration of supplemental fluid boluses before continuous nebulized albuterol appeared to provide a significant protective effect. The clinical impact and the significance of diastolic hypotension and the importance of prophylactic administration of intravenous fluid boluses in patients experiencing status asthmaticus are yet to be determined.
a Children's Memorial Hermann Hospital (Previous), The Children's Hospital of San Antonio, Christus Santa Rosa (Current) , San Antonio , TX , USA .
Sarah
S
Wisecup
Shannan
S
Eades
Syed Shahrukh
SS
Hashmi
Cheryl
C
Samuels
Ricardo Alberto
RA
Mosquera
D000367:Age Factors; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D005260:Female; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D007022:Hypotension / Q000139:chemically induced*; D007223:Infant; D008297:Male; D009330:Nebulizers and Vaporizers; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D012737:Sex Factors; D013224:Status Asthmaticus / Q000188:drug therapy
D001993:Bronchodilator Agents; D000420:Albuterol
Asthma; continuous albuterol; diastolic hypotension; status asthmaticus